Was the erection effect really a surprise, or is that a polished story?
The file opens on a missed angina tablet
Enter the miss. Annotate the side-effect line that moved the programme. Stamp the IIEF papers. Close the angina column.
Sandwich missed angina before the brand name existed. That is the first stamp on THL-S03, not a cute origin myth.
UK-92,480 sat in a cardiovascular programme because PDE5 looked like a way to dilate coronaries and ease platelets. Early clinical work did not deliver a useful anti-anginal story.
The discovery file opens on that gap. Everything after - IIEF, 25/50/100 mg, empty-plate timing - is a repositioned programme, not the original question.
I will not rewrite the miss as destiny. Plenty of PDE5 ideas died. This one lived because volunteers said something the angina score did not.
Label counseling lives on the Viagra formulary page. This study keeps the test trail.
How this desk stamps a discovery miss
- Miss: angina / hypertension clinical signal too weak to carry.
- Hinge: reproducible erection reports under stimulation.
- Instrument: IIEF (1997) plus event logs.
- Hit: Goldstein 1998 dose ladder; FDA March 1998.
Write the failed indication first. UK-92,480 did not earn angina. That sentence stays at the top so the ED hit does not look like a planned product launch.
Write the side-effect that moved the programme. Erection reports in Phase I are the hinge, not a punchline.
Write the instrument. IIEF plus event logs plus a global question - that is how a hallway line became a file.
Write the ladder. 25, 50, 100 mg. This desk's 100 mg lock is the top rung as context, not a start-for-all rule.
Close the cart question. Discovery tests do not quote a cash window.
IIEF turned hallway talk into a scored domain
Rosen's 1997 Urology paper gave investigators a 15-item index with five domains. Erectile function (questions 1-5 and 15) became the number regulators could argue about.
Event logs and a global-efficacy yes/no sat beside IIEF. Hardness scales without a domain total were no longer enough for a modern ED file.
Orgasm, desire, intercourse satisfaction, and overall satisfaction were scored separately so a libido miss would not hide inside an erection win.
Without IIEF, the Sandwich side-effect line stays a story. With IIEF, a 24-week randomized tablet can be stamped.
Later daily tadalafil papers borrowed the same EF domain. That borrowing does not make this discovery file a half-life study.
Domain totals let a reviewer see whether desire moved while erection did not. That split kept libido claims from hiding inside a hardness win.
Global yes/no without IIEF would have been a brochure. The 15-item index is why March 1998 could be stamped as a file, not a rumor.
Blue tint is a PDE6 footnote, not a mystery
Sildenafil is a little less picky about PDE6 in the retina than some later cousins. Transient blue tint or brightness sits on that footnote.
The effect tracks plasma, then leaves. It is not an IIEF domain and it is not proof the tablet 'hit the brain.'
Sudden vision loss is a different file - NAION has a labeled warning. I will not fold that rare event into the ordinary blue-tint paragraph.
Hearing loss, likewise, is a rare labeled mark, not a discovery-trial primary.
Men who need crisp color work at night should hear the PDE6 line before the first 100 mg, not after they panic in a parking lot.
Photographers and night drivers ask about this more than the IIEF papers do. I answer with the enzyme name, then the time course, then the rare NAION fork.
Later cousins advertised less color change. That is a selectivity footnote, not proof that Sandwich chemistry was sloppy.
Why 100 mg still follows an empty plate
A high-fat meal delays sildenafil and cuts Cmax. The original timing advice - about an hour before, on a quieter stomach - is PK, not folklore.
This site's 100 mg lock is the high chip from the Goldstein ladder. Starting there in a man with a full steak dinner is how a 'failed tablet' story gets written in a clinic.
Alcohol was capped in the protocol language - not more than two drinks near activity. That was a safety frame, not a cocktail endorsement.
CYP3A4 inhibitors stretch the same exposure the empty plate was meant to keep predictable. Erythromycin and ritonavir are not side notes on a 100 mg night.
If the plate cannot be empty, the honest stamp is 'expect a slower, weaker peak,' not 'take a second 100 mg.'
Grapefruit and strong CYP3A4 inhibitors stretch the same peak the empty plate was meant to keep tidy. I annotate those bottles before I blame the diamond.
Once-daily stacking was never the discovery design. A leftover 100 mg the next morning is a new exposure, not a continuation arm.
Revatio is a different stamp on the same molecule
Pulmonary arterial hypertension later earned its own brand and a different dose rhythm. That is a walk-distance and hemodynamics family, not an IIEF family.
Importing Revatio numbers into a 100 mg ED night is the same category error as importing Adcirca into a 2.5 mg breakfast.
The angina miss still matters here. The molecule never became a routine anti-ischemic. PAH success did not reopen the original chest-pain column.
Nitrate rules travel with the molecule across brands. A PAH patient on nitrates is not a special exception because the bottle says Revatio.
Stay on the ED discovery trail on this page. PAH has its own papers.
Goldstein's 24-week dose ladder, 25 to 100
Goldstein's 1998 NEJM dose-response study randomized 532 men to placebo or 25, 50, or 100 mg for 24 weeks, taken about an hour before activity, not more than once a day.
IIEF at 12 and 24 weeks, a global-efficacy question, and event logs were the scored set. That is the hit after the angina miss.
One hundred milligrams sat at the top of that ladder. This desk locks 100 mg as context because it is the high labeled ED chip from that original file, not because every man should start there.
Headache, flushing, dyspepsia, and color-vision change were the dose-related adverse marks already visible in the 1990s package.
More than 4,500 people had been exposed across 21 ED trials by the 1997 registration push. The angina column stayed empty. The ED column was full enough to file.
Fixed-dose blister rows in Goldstein's design kept men from titrating themselves mid-study. That discipline is why 25, 50, and 100 mg can still be read as separate rungs.
European approval followed in September 1998. The US March stamp is the one this file dates; the EMEA date is a second clerk mark, not a second discovery.
Sandwich built UK-92,480 for chest pain
1989
UK-92,480 synthesized at Sandwich as a PDE5 candidate for angina and hypertension.
1991
First clinical exposure; angina signal stays weak; erection reports accumulate.
1997
Rosen publishes IIEF, giving ED trials a scored domain language.
1998
FDA approves Viagra in March after the ED trial package, including Goldstein's dose ladder.
Pyrazolopyrimidine PDE5 work at Pfizer's Sandwich, Kent site in the late 1980s produced UK-92,480, later sildenafil citrate.
Platelet and vessel models looked promising. An IC50 near 3.5 nM on platelet PDE5 with selectivity over PDE1-4 was enough to take the compound into people in 1991.
Morriston Hospital in Swansea ran early clinical work. Ian Osterloh's group saw little anti-anginal punch and a consistent erection report days after dosing.
Hypertension hopes faded with the angina hopes. The molecule was a mediocre anti-ischemic and a surprisingly specific genital vasodilator under sexual stimulation.
Simon Campbell's chemistry group had been hunting a clean PDE5 tool. They found one. The disease it eventually treated was not the disease on the first protocol page.
Registration dossiers in 1997-98 therefore carried ED exposures, not a completed anti-anginal package. That filing choice is the paper trail of the miss.
Kent lab notebooks still read as cardiovascular chemistry. The clinic diaries are what changed the stamp.
Volunteers reported erections. The angina signal did not.
Phase I diaries mentioned penile erections more reliably than they mentioned less chest pain on exertion. That imbalance is the whole pivot.
Sexual stimulation still had to be present. The tablet amplified nitric oxide already being released. It did not invent desire, which later counseling still has to say out loud.
Pfizer could have stopped. Many cardiovascular also-rans stop. The decision to reopen the file as an ED programme is the second stamp, after the miss.
Nitrate collision was already visible in the mechanism. Any later ED trial inherited an absolute contraindication the angina team would have recognized.
I keep the volunteer line humble. Anecdote opened the door. IIEF had to walk through it.
Early-room stimulations were ordinary - not a staged marketing night. The report still had to survive a scored domain later.
Stopping after Phase I would have left UK-92,480 as a footnote in a PDE5 review. Continuing meant building an instrument the angina team never needed.
What the discovery file keeps
Sandwich built a chest-pain tablet that missed. The ED file opened because volunteers and then IIEF said the same thing in two languages.
One hundred milligrams remains the high chip on this desk's lock, usually after an empty plate, never with a nitrate.
Blue tint is PDE6. PAH is another stamp. Neither rewrites the angina miss.
Take the nitrate list and the meal timing to a clinician who can see you. THL-S03 is a discovery file, not a prescription.
Talk with your own clinician or pharmacist before you change a tablet or a dose. Open the ledger disclaimer.
Last Updated
Reader mail
Reader questions on this article
Answered by Dr. Liam Hartwell, MD · Urology & men's health
Readers ask how a failed angina tablet became an ED file. Names are editorial. I stay with Sandwich, IIEF, and the 25-100 mg ladder - not with a checkout line.
The chemistry was aimed at PDE5 for vessels and platelets. The first protocols were angina and blood pressure. What surprised the team was the imbalance: little anti-anginal punch, consistent erection reports. Ian Osterloh's early clinical notes are the hinge, not a press kit. I still call it a miss plus a hinge, not destiny. Plenty of PDE5 ideas died without a second file.
Why do you keep saying IIEF instead of 'it just works'?
Because hallway talk cannot be filed. Rosen's 1997 index gave a 15-item, five-domain score. Erectile function is questions 1-5 and 15, total 1 to 30. Goldstein then ran that instrument for 24 weeks across 25, 50, and 100 mg. That is the hit. 'It just works' is how a discovery file turns into a commercial. I will not stamp that.
Should I start at 100 mg because that is the lock on this site?
No. One hundred milligrams is this desk's locked context - the top of the original ladder - not a universal first tablet. Many men start lower and only step up if the EF domain and the event log stay thin. A full meal plus 100 mg is a common way to write a false failure. Ask the person who can see your nitrate list. The formulary line keeps the holds.
I took it after a burger and nothing happened. Failed drug?
Failed timing, maybe. A fatty meal delays the peak and cuts Cmax. The original advice was about an hour before, on a quieter stomach. Sexual stimulation still has to be there. A tablet on a full stomach plus no arousal is two misses stacked. Do not swallow a second 100 mg the same night to 'catch up.' That was never a Goldstein arm.
The blue tint scared me. Is that damage?
Ordinary blue tint or brightness is a PDE6 crossover that tracks the plasma and then leaves. It is not an IIEF score and it is not proof of retinal injury. Sudden vision loss is a different warning - NAION - and that is same-day care, not a wait-and-see tint. I mention PDE6 before the first high chip so the parking-lot panic is less likely.
Did any angina benefit ever show up later?
Not as a labeled anti-anginal. The molecule later found a pulmonary hypertension brand with a different dose rhythm and different endpoints. That PAH success does not reopen the original chest-pain column. I will not tell a man with exertional angina that UK-92,480 'kind of worked after all.' Chest pain on a PDE5 tablet is still an emergency sentence: name the drug, skip the nitroglycerin.
How is this different from the tadalafil half-life study?
That file starts with 17.5 hours and daily versus PRN arms. This file starts with a missed indication and an instrument that rescued a side-effect line. Sildenafil's half-life is short - about four hours - which is why it never became a true once-daily ED tablet. Read the tadalafil study for clock math. Stay here for the miss-then-hit trail.
Why empty plate and not 'with food to be gentle'?
Gentleness is not the PK goal. Predictable Cmax is. Food makes sildenafil later and lower. If dyspepsia is the problem, that is a different counseling mark - and it was already a dose-related adverse in the 1990s package. Do not solve an empty-plate delay by adding a second tablet.
Can I use a Revatio tablet as a cheaper 100 mg stand-in?
That is a brand-and-dose category error. Revatio is a PAH rhythm, not the Goldstein ED ladder. Splitting or substituting across brands without the prescriber is how people invent exposures this discovery file never studied. I stamp them apart. Your clinician can talk cost. This page will not.
General education from a clinician, not personal medical advice. Bring your own history to your own prescriber.